Unity Biotechnology Inc (UBX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Unity Biotechnology Inc (UBX) has a cash flow conversion efficiency ratio of 31.010x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.36 Million) by net assets ($-205.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Unity Biotechnology Inc worth for the company's overall valuation and market capitalisation.
Unity Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Unity Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Unity Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unity Biotechnology Inc ranked by their cash flow conversion efficiency. See Unity Biotechnology Inc cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tlou Energy Ltd
AU:TOU
|
-1.918x |
|
Emetals Ltd
AU:EMT
|
-0.080x |
|
LakeShore Biopharma Co., Ltd
NYSE:LSBCF
|
-0.001x |
|
Arkadia Digital Media Tbk PT
JK:DIGI
|
0.084x |
|
Pensana Rare Earths Plc
LSE:PRE
|
-0.065x |
|
Next Mediaworks Limited
NSE:NEXTMEDIA
|
0.011x |
|
Baillie Gifford UK Growth Fund PLC
LSE:BGUK
|
0.007x |
|
Linkage Global Inc Ordinary Shares
NASDAQ:LGCB
|
-0.187x |
Annual Cash Flow Conversion Efficiency for Unity Biotechnology Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Unity Biotechnology Inc from 2016 to 2024. View Unity Biotechnology Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.49 Million | $-20.86 Million | -3.213x | -136.07% |
| 2023-12-31 | $28.40 Million | $-38.65 Million | -1.361x | -78.30% |
| 2022-12-31 | $66.85 Million | $-51.03 Million | -0.763x | -0.92% |
| 2021-12-31 | $59.57 Million | $-45.06 Million | -0.756x | +19.97% |
| 2020-12-31 | $82.88 Million | $-78.33 Million | -0.945x | -57.53% |
| 2019-12-31 | $120.71 Million | $-72.42 Million | -0.600x | -70.27% |
| 2018-12-31 | $160.69 Million | $-56.62 Million | -0.352x | +16.55% |
| 2017-12-31 | $90.84 Million | $-38.36 Million | -0.422x | -206.95% |
| 2016-12-31 | $-41.54 Million | $-16.40 Million | 0.395x | -- |
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more